Affiliation:
1. Department of Pharmaceutical Sciences , MCPHS University , 19 Foster Street , Worcester MA 01608, United States
Abstract
:
Chronic myeloid leukemia (CML) is a blood cancer predominantly affecting older adult patients. According
to the American Cancer Society, an estimated 8,860 people will be diagnosed with CML in 2022. Treatments for CML
have evolved with a focus on CML phase severity or progression. Overall, there have been some breakthrough treatment
options for a high percentage of patients with CML. This is largely due to the discovery of tyrosine kinase inhibitors
(TKI); however, drug resistance continues to present a significant challenge in the management of CML disease.
The use of interferon (IFN), antimetabolites, and bone marrow transplants provides alternative treatment options,
but also presents limitations, including severe side effects, toxicity, and graft versus host disease. Nanomedicine
has demonstrated benefits in terms of efficacy, often reducing or eliminating unwanted toxicities associated with the
use of conventional drug agents. This review summarizes rational molecular targets of CML drugs and provides highlights
of current FDA-approved agents for the treatment of CML. Additionally, this communication includes an overview
of the limitations of conventional treatments and how nanomedicine has addressed challenges encountered during
CML treatment.
Publisher
Bentham Science Publishers Ltd.
Subject
Cancer Research,Pharmacology,Molecular Medicine
Reference71 articles.
1. Singh R.; Lillard J.W.; Jr Nanoparticle-based targeted drug delivery. Exp Mol Pathol 2009,86(3),215-223
2. Younis M.A.; Tawfeek H.M.; Abdellatif A.A.H.; Abdel-Aleem J.A.; Harashima H.; Clinical translation of nanomedicines: Challenges, opportunities, and keys. Adv Drug Deliv Rev 2022,181,114083
3. Bobo D.; Robinson K.J.; Islam J.; Thurecht K.J.; Corrie S.R.; Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date. Pharm Res 2016,33(10),2373-2387
4. Davis A.S.; Viera A.J.; Mead M.D.; Leukemia: An overview for primary care. Am Fam Physician 2014,89(9),731-738
5. Chronic Myeloid Leukemia Cancer website. 2020. Available from: https://www.cancer.gov/types/leukemia/hp/cml-treatment-pdq#_6